Skip to main content

Yimmugo Dosage

Generic name: HUMAN IMMUNOGLOBULIN G 10g in 100mL
Dosage form: injection
Drug class: Immune globulins

Medically reviewed by Drugs.com. Last updated on Jul 31, 2024.

For intravenous use only.

Dosage

Table 1: Recommended Dosage and Administration
Dose Infusion
Number		 Initial Infusion
Rate		 Maintenance
Infusion Rate (if
tolerated)
300–800 mg/kg
(3–8 mL/kg)
every 3–4 weeks		 For the 1st
infusion		 0.5 mg/kg/min
(0.005 mL/kg/min)
for 30 minutes		 Gradually increase every 30 minutes up
to 3.0 mg/kg/min (0.03 mL/kg/min).
300–800 mg/kg
(3–8 mL/kg)
every 3–4 weeks		 From the 2nd
infusion		 0.5 mg/kg/min
(0.005 mL/kg/min)
for 30 minutes		 Gradually increase up to 13 mg/kg/min
(0.13 mL/kg/min).

The dosage may be adjusted over time to achieve the desired trough levels and clinical response.

Preparation and Handling

  • YIMMUGO is a clear to slightly opalescent, colorless to pale yellow solution. Inspect visually for particulate matter and discoloration prior to administration, whenever the solution and container permit. Do not use if the liquid is cloudy or turbid, discolored, or if it contains visible particulate matter.
  • Do not shake.
  • YIMMUGO should be at room or body temperature at the time of administration.
  • Do not mix with other IGIV products or other intravenous medications.
  • Do not dilute.
  • YIMMUGO is for single use only. It contains no preservatives. Promptly use any vial that has been entered. Discard partially used vials and unused product in accordance with local requirements.
  • Do not use YIMMUGO after expiration date on the product label.

Administration

Administer YIMMUGO at room temperature or body temperature by the intravenous route. Do not mix with any intravenously administered medications. For rate of infusion, refer to Table 1. Monitor patient vital signs throughout the infusion. Slow or stop the infusion if adverse reactions occur. If symptoms subside promptly, the infusion may be resumed at a lower rate that is comfortable for the patient.

Ensure that patients with pre-existing renal insufficiency are not volume depleted. For patients judged to be at risk for renal dysfunction or thrombotic events, administer YIMMUGO at the minimum infusion rate practicable, and consider discontinuation of administration if renal function deteriorates.

Hydrate the patient adequately prior to the initiation of infusion.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer